Mga Batayang Estadistika
| LEI | 549300DJ0Q0D9TVY5O19 |
| CIK | 1585608 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Jaguar Health, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 19, 2025 |
EX-99.1 Exhibit 99.1 Jaguar Health Reports Approval of All Proposals at August 2025 Annual Meeting of Stockholders Jaguar CEO Lisa Conte presenting August 20 at Emerging Growth Conference to provide updates on near-term catalysts; Click here to register As announced, initial proof-of-concept results from the ongoing investigator-initiated trial in Abu Dhabi show crofelemer reduced the required tot |
|
| August 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2025 JAGUAR HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36714 46-2956775 (State or other jurisdiction of incorporation) (Commission Fil |
|
| August 14, 2025 |
JAGUAR HEALTH, INC. Up to $3,378,239 Shares of Common Stock 424B5 Filed pursuant to Rule 424(b)(5) File No. 333-278861 Supplement No. 6 dated August 14, 2025 To Prospectus Supplement dated May 23, 2024 (To Prospectus Dated May 1, 2024) JAGUAR HEALTH, INC. Up to $3,378,239 Shares of Common Stock This supplement No. 6 (this “Supplement) amends and supplements certain information contained in the prospectus supplement, dated May 23, 2024, and as amended by th |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001 |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2025 Jaguar Health, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36714 46-2956775 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| August 14, 2025 |
EX-10.1 Exhibit 10.1 August 14, 2025 Jaguar Health, Inc. 200 Pine Street, Suite 400 San Francisco, CA 94104 Attn: Lisa A. Conte, President & CEO Dear Ms. Conte: Reference is made to the At The Market Offering Agreement, dated as of December 10, 2021 (the “ATM Agreement”), between Jaguar Health, Inc. (the “Company”) and Ladenburg Thalmann & Co., Inc. (the “Ladenburg”), as amended by way of letter a |
|
| August 6, 2025 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| July 30, 2025 |
Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-288927 481,150 Shares of Common Stock Issuable Upon the Conversion of Outstanding Replacement Notes 928,582 Shares of Common Stock Issuable Upon the Exercise of Outstanding Common Warrants This prospectus relates to the resale of up to 1,409,732 shares of Jaguar Health, Inc. (the “Company,” “we,” “our” or “us”) voting common s |
|
| July 24, 2025 |
As filed with the Securities and Exchange Commission on July 24, 2025 S-3 Table of Contents As filed with the Securities and Exchange Commission on July 24, 2025 Registration No. |
|
| July 24, 2025 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Jaguar Health, Inc. |
|
| July 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a -6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material under §240. |
|
| July 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material under §240. |
|
| June 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2025 Jaguar Health, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36714 46-2956775 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| June 30, 2025 |
Streeterville Series M Exchange Agreement. Exhibit 10.2 THE EXCHANGE CONTEMPLATED HEREIN IS INTENDED TO COMPORT WITH THE REQUIREMENTS OF SECTION 3(a)(9) OF THE SECURITIES ACT OF 1933, AS AMENDED. EXCHANGE AGREEMENT This Exchange Agreement (this “Agreement”) is entered into as of June 27, 2025 (the “Effective Date”) by and between Streeterville Capital, LLC, a Utah limited liability company (“Investor”), and Jaguar Health, Inc., a Delaware |
|
| June 30, 2025 |
EX-3.1 Exhibit 3.1 JAGUAR HEALTH, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES M PERPETUAL PREFERRED STOCK Pursuant to Section 151 of the General Corporation Law of the State of Delaware The undersigned, Lisa A. Conte and Carol R. Lizak, do hereby certify that: 1. They are the Chief Executive Officer/President and Chief Financial Officer, respectively, of Jaguar |
|
| June 30, 2025 |
Iliad Series M Exchange Agreement. Exhibit 10.1 THE EXCHANGE CONTEMPLATED HEREIN IS INTENDED TO COMPORT WITH THE REQUIREMENTS OF SECTION 3(a)(9) OF THE SECURITIES ACT OF 1933, AS AMENDED. EXCHANGE AGREEMENT This Exchange Agreement (this “Agreement”) is entered into as of June 27, 2025 (the “Effective Date”) by and between Iliad Research and Trading, L.P., a Utah limited partnership (“Investor”), and Jaguar Health, Inc., a Delaware |
|
| June 27, 2025 |
424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-288202 492,612 Shares of Common Stock Issuable Upon the Exercise of Outstanding Common Warrants 14,778 Shares of Common Stock Issuable Upon the Exercise of Outstanding Placement Agent Warrants This prospectus relates to the resale of up to 507,390 shares of Jaguar Health, Inc. (the “Company,” “we,” “our” or “us”) voting |
|
| June 27, 2025 |
JAGUAR HEALTH, INC. Up to $3,378,239 Shares of Common Stock Filed pursuant to Rule 424(b)(5) File No. 333-278861 Supplement No. 5 dated June 27, 2025 To Prospectus Supplement dated May 23, 2024 (To Prospectus Dated May 1, 2024) JAGUAR HEALTH, INC. Up to $3,378,239 Shares of Common Stock This supplement No. 5 (this “Supplement) amends and supplements certain information contained in the prospectus supplement, dated May 23, 2024, and as amended by the supple |
|
| June 25, 2025 |
June 25, 2025 Via EDGAR U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Jaguar Health, Inc. Registration Statement on Form S-3 File No. 333-288202 Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Jaguar Health, Inc., a Delaware corporation (the “Registrant”), hereby requests the above-referenced Registration |
|
| June 24, 2025 |
Form of Note Exchange and Warrant Purchase Agreement EXHIBIT 10.1 THE EXCHANGE CONTEMPLATED HEREIN IS INTENDED TO COMPORT WITH THE REQUIREMENTS OF SECTION 3(A)(9) OF THE SECURITIES ACT OF 1933, AS AMENDED. NOTE EXCHANGE AND WARRANT PURCHASE AGREEMENT THIS NOTE EXCHANGE AND WARRANT PURCHASE AGREEMENT (this “Agreement”), dated as of June 23, 2025 (the “Execution Date”), is entered into by and between JAGUAR HEALTH, INC., a Delaware corporation, (the “ |
|
| June 24, 2025 |
Exhibit 4.1 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS NOTE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECU |
|
| June 24, 2025 |
Exhibit 99.1 Jaguar Health Announces Extension of the Maturity Date of its Convertible Promissory Notes from Recently Closed Bridge Financing to January 30, 2026 Company’s CEO, board members, other C-suite members, and institutional and accredited investors are participants in the extension of the bridge financing San Francisco, CA (June 24, 2025): Jaguar Health, Inc. (NASDAQ:JAGX) (“Jaguar” or “t |
|
| June 24, 2025 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES AS TO WHICH THIS SECURITY MAY BE EXERCISED HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REG |
|
| June 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2025 JAGUAR HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36714 46-2956775 (State or other jurisdiction of incorporation) (Commission File |
|
| June 20, 2025 |
As filed with the Securities and Exchange Commission on June 20, 2025 S-3 Table of Contents As filed with the Securities and Exchange Commission on June 20, 2025 Registration No. |
|
| June 20, 2025 |
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Jaguar Health, Inc. |
|
| May 22, 2025 |
Form of Securities Purchase Agreement Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of May 20, 2025, between Jaguar Health, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set f |
|
| May 22, 2025 |
Form of Common Stock Purchase Warrant Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES AS TO WHICH THIS SECURITY MAY BE EXERCISED HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REG |
|
| May 22, 2025 |
Exhibit 99.1 Jaguar Health Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules San Francisco, CA (May 21, 2025): Jaguar Health, Inc. (NASDAQ:JAGX) (“Jaguar” or “the Company”), today announced that it has entered into definitive agreements for the purchase and sale of 246,306 shares of common stock at a purchase price of $6.09 per share in a registered direct o |
|
| May 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2025 JAGUAR HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36714 46-2956775 (State or other jurisdiction of incorporation) (Commission File N |
|
| May 22, 2025 |
EX-4.2 3 d927226dex42.htm EX-4.2 Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES AS TO WHICH THIS SECURITY MAY BE EXERCISED HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EX |
|
| May 22, 2025 |
JAGUAR HEALTH, INC. 246,306 Shares of Common Stock Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-278861 PROSPECTUS SUPPLEMENT (TO PROSPECTUS DATED MAY 1, 2024) JAGUAR HEALTH, INC. 246,306 Shares of Common Stock Pursuant to this prospectus supplement and the accompanying prospectus, we are offering 246,306 shares of our voting common stock, $0.0001 par value per share (“Common Stock”), at an offering price of $6.09 per sha |
|
| May 21, 2025 |
JAGUAR HEALTH, INC. Up to $2,177,438 Shares of Common Stock 424B5 Filed pursuant to Rule 424(b)(5) File No. 333-278861 Supplement No. 4 dated May 21, 2025 To Prospectus Supplement dated May 23, 2024 (To Prospectus Dated May 1, 2024) JAGUAR HEALTH, INC. Up to $2,177,438 Shares of Common Stock This supplement No. 4 (this “Supplement) amends and supplements certain information contained in the prospectus supplement, dated May 23, 2024, and as amended by the s |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2025 Jaguar Health, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36714 46-2956775 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| May 15, 2025 |
Iliad Common Stock Exchange Agreement. Exhibit 10.1 THE EXCHANGE CONTEMPLATED HEREIN IS INTENDED TO COMPORT WITH THE REQUIREMENTS OF SECTION 3(a)(9) OF THE SECURITIES ACT OF 1933, AS AMENDED. EXCHANGE AGREEMENT This Exchange Agreement (this “Agreement”) is entered into as of May 13, 2025 (the “Effective Date”) by and between Iliad Research and Trading, L.P., a Utah limited partnership (“Lender”), and Jaguar Health, Inc., a Delaware cor |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 00 |
|
| May 15, 2025 |
Streeterville Exchange Agreement. Exhibit 10.2 THE EXCHANGE CONTEMPLATED HEREIN IS INTENDED TO COMPORT WITH THE REQUIREMENTS OF SECTION 3(a)(9) OF THE SECURITIES ACT OF 1933, AS AMENDED. EXCHANGE AGREEMENT This Exchange Agreement (this “Agreement”) is entered into as of May 14, 2025 (the “Effective Date”) by and between Streeterville Capital, LLC, a Utah limited liability company (“Investor”), and Jaguar Health, Inc., a Delaware c |
|
| May 15, 2025 |
Exhibit 3.1 JAGUAR HEALTH, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES L PERPETUAL PREFERRED STOCK Pursuant to Section 151 of the General Corporation Law of the State of Delaware The undersigned, Lisa A. Conte and Carol R. Lizak, do hereby certify that: 1. They are the Chief Executive Officer/President and Chief Financial Officer, respectively, of Jaguar Health |
|
| May 15, 2025 |
EX-99.1 Exhibit 99.1 Jaguar Health Reports First Quarter 2025 Financials The combined net Q1 2025 revenue of approximately $2.2 million for prescription and non-prescription products, including license revenue, decreased approximately 6% versus net Q1 2024 revenue of $2.4 million and 37% versus net Q4 2024 revenue of $3.5 million Mytesi prescription volume increased by approximately 1.8% in Q1 202 |
|
| May 15, 2025 |
Exhibit 10.3 February 4, 2025 Jaguar Health, Inc. 200 Pine Street, Suite 400 San Francisco, CA 94104 Attn: Lisa A. Conte, President & CEO Dear Ms. Conte: Reference is made to the At The Market Offering Agreement, dated as of December 10, 2021 (the “ATM Agreement”), between Jaguar Health, Inc. (the “Company”) and Ladenburg Thalmann & Co., Inc. (the “Ladenburg”), as amended by way of letter agreemen |
|
| May 15, 2025 |
Iliad Series L Exchange Agreement. Exhibit 10.3 THE EXCHANGE CONTEMPLATED HEREIN IS INTENDED TO COMPORT WITH THE REQUIREMENTS OF SECTION 3(a)(9) OF THE SECURITIES ACT OF 1933, AS AMENDED. EXCHANGE AGREEMENT This Exchange Agreement (this “Agreement”) is entered into as of May 14, 2025 (the “Effective Date”) by and between Iliad Research and Trading, L.P., a Utah limited partnership (“Investor”), and Jaguar Health, Inc., a Delaware c |
|
| May 9, 2025 |
Jaguar Health, Inc. (NASDAQ: JAGX) Overview – May 2025 Exhibit 99.1 Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this presentation, including statements regarding plans by Jaguar Health, Inc. (“Jaguar” or t |
|
| May 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2025 Jaguar Health, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36714 46-2956775 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| May 7, 2025 |
Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-286550 631,922 Shares of Common Stock Issuable Upon the Conversion of Outstanding Notes 622,584 Shares of Common Stock Issuable Upon the Exercise of Outstanding Common Warrants 37,376 Shares of Common Stock Issuable Upon the Exercise of Outstanding Placement Agent Warrants This prospectus relates to the resale of up to 1,291,8 |
|
| May 5, 2025 |
JAGUAR HEALTH, INC. Up to $5,664,382 Shares of Common Stock Filed pursuant to Rule 424(b)(5) File No. 333-278861 Supplement No. 3 dated May 5, 2025 To Prospectus Supplement dated May 23, 2024 (To Prospectus Dated May 1, 2024) JAGUAR HEALTH, INC. Up to $5,664,382 Shares of Common Stock This supplement No. 3 (this “Supplement”) amends and supplements certain information contained in the prospectus supplement, dated May 23, 2024, and as amended by the supplem |
|
| May 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2025 Jaguar Health, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36714 46-2956775 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| May 5, 2025 |
CORRESP May 5, 2025 Via EDGAR U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Jaguar Health, Inc. Registration Statement on Form S-3 File No. 333-286550 Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Jaguar Health, Inc., a Delaware corporation (the “Registrant”), hereby requests the above-referenced Registr |
|
| May 5, 2025 |
EX-10.1 Exhibit 10.1 WAIVER This Waiver is entered into effective as of May 5, 2025, by and between Jaguar Health, Inc., a Delaware corporation (the “Company”), and each buyer identified on the signature pages hereto (each, including its successors and assigns, a “Buyer” and collectively, the “Buyers”), pursuant to that certain Securities Purchase Agreement, dated as of March 26, 2025, by and betw |
|
| May 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2025 Jaguar Health, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36714 46-2956775 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| April 30, 2025 |
Exhibit 99.1 Proof-of-Concept Results Show Crofelemer Reduced Total Parenteral Nutrition in Patients with Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF) by up to 27% and 12.5% – Potential to Modify Disease Progression in Intestinal Failure Patients Jaguar to host investor webcast today at 8:30 AM Eastern to review the initial results fr |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2025 Jaguar Health, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36714 46-2956775 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| April 28, 2025 |
About Crofelemer About the Jaguar Health Family of Companies Forward-Looking Statements Contact: Jaguar Health to Present Initial Results from the Proof-of-Concept Study of Crofelemer for the Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF) During an April 30 Investor Webcast The webcast will review the MVID and SBS-IF patient experience, the impact of crofelemer on disease progression and quality of life in MVID and SBS-IF, and poss |
|
| April 28, 2025 |
FORM 8-K Item 7.01 Regulation FD Disclosure. Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2025 Jaguar Health, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36714 46-2956775 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| April 25, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2025 Jaguar Health, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36714 46-2956775 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| April 25, 2025 |
Reed Smith LLP 599 Lexington Avenue New York, NY 10022 +212 521 5400 Fax +1 212 521 5450 reedsmith. |
|
| April 25, 2025 |
Jaguar Health, Inc. (NASDAQ: JAGX) Overview – April 2025 Jaguar Health, Inc. (NASDAQ: JAGX) Overview – April 2025 Forward-Looking Statements 2 This presentation contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this presentation, including statements regarding plans by Jaguar Health, Inc. (“Jaguar” or the “Compa |
|
| April 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2025 Jaguar Health, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36714 46-2956775 (State or Other Jurisdiction of Incorporation) (Commission |
|
| April 25, 2025 |
As filed with the Securities and Exchange Commission on April 25, 2025 Table of Contents As filed with the Securities and Exchange Commission on April 25, 2025 Registration No. |
|
| April 21, 2025 |
Jaguar Health, Inc. (NASDAQ: JAGX) Overview – April 2025 Jaguar Health, Inc. (NASDAQ: JAGX) Overview – April 2025 Forward-Looking Statements 2 This presentation contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this presentation, including statements regarding plans by Jaguar Health, Inc. (“Jaguar” or the “Compa |
|
| April 21, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 18, 2025 Jaguar Health, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36714 46-2956775 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| April 15, 2025 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Jaguar Health, Inc. |
|
| April 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file |
|
| April 15, 2025 |
As filed with the Securities and Exchange Commission on April 15, 2025 As filed with the Securities and Exchange Commission on April 15, 2025 Registration Statement No. |
|
| April 15, 2025 |
As filed with the Securities and Exchange Commission on April 15, 2025 Table of Contents As filed with the Securities and Exchange Commission on April 15, 2025 Registration No. |
|
| April 15, 2025 |
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Jaguar Health, Inc. |
|
| April 4, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2025 Jaguar Health, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36714 46-2956775 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| April 4, 2025 |
Jaguar Health Announces Closing of Bridge Financing Priced At-The-Market Under Nasdaq Rules Jaguar Health Announces Closing of Bridge Financing Priced At-The-Market Under Nasdaq Rules San Francisco, CA (April 1, 2025): Jaguar Health, Inc. |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K Table of Contents d UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NO. |
|
| March 31, 2025 |
Jaguar Health, Inc. Insider Trading Policy. Exhibit 19.1 JAGUAR ANIMAL HEALTH, INC. POLICY ON INSIDER TRADING AND TIPPING (to be effective upon the Company’s initial public offering) INTRODUCTION In the normal course of business, officers, directors and employees of Jaguar Animal Health, Inc. (“Company”) may come into possession of material nonpublic information. This information is considered the property of the Company. In particular, if |
|
| March 31, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2025 Jaguar Health, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36714 46-2956775 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| March 31, 2025 |
Subsidiaries of the Registrant. Exhibit 21.1 SUBSIDIARIES OF JAGUAR HEALTH, INC. Name of Subsidiary State or Other Jurisdiction of Incorporation or Organization Napo Pharmaceuticals, Inc. Delaware Napo Therapeutics S.p.A. Italy |
|
| March 31, 2025 |
Jaguar Health Reports 2024 Financials: 2024 Net Revenue Up Approximately 20% Over 2023 The total net revenue for the year ended December 31, 2024 of approximately $11. |
|
| March 26, 2025 |
NEITHER THIS SECURITY NOR THE SECURITIES AS TO WHICH THIS SECURITY MAY BE EXERCISED HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION ST |
|
| March 26, 2025 |
REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of March 26, 2025 (the “Execution Date”), is entered into by and between JAGUAR HEALTH, INC. |
|
| March 26, 2025 |
NEITHER THIS SECURITY NOR THE SECURITIES AS TO WHICH THIS SECURITY MAY BE EXERCISED HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION ST |
|
| March 26, 2025 |
NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. |
|
| March 26, 2025 |
Jaguar Health CEO, Board Members, Other C-Suite Members, and Institutional and Accredited Investors Invest in $3. |
|
| March 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2025 Jaguar Health, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36714 46-2956775 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| March 26, 2025 |
SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of March 26, 2025, (the “Execution Date”), is entered into by and between Jaguar Health, Inc. |
|
| March 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2025 Jaguar Health, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36714 46-2956775 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| March 18, 2025 |
Jaguar Health, Inc. Announces Reverse Stock Split Reverse split approved at March 2025 Special Meeting of Stockholders Shares of Jaguar Health common stock to begin trading on split-adjusted basis on March 24, 2025 San Francisco, CA (March 18, 2025): Jaguar Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”) today announced that the Company will effect a reverse stock split of its issued and o |
|
| March 18, 2025 |
CERTIFICATE OF NINTH AMENDMENT TO THE THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF JAGUAR HEALTH, INC. |
|
| March 13, 2025 |
Jaguar Health Reports Approval of All Proposals at March 2025 Special Meeting of Stockholders Jaguar expects first results in Q2 2025 of proof-of-concept investigator-initiated trials of crofelemer for the rare diseases short bowel syndrome with intestinal failure and microvillus inclusion disease FDA meeting expected in Q2 2025 on the statistically significant results of the Phase 3 OnTarget trial of crofelemer in the prespecified subgroup of patients with breast cancer San Francisco, CA (March 13, 2025): Jaguar Health, Inc. |
|
| March 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2025 Jaguar Health, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36714 46-2956775 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| February 27, 2025 |
CERTIFICATE OF DESIGNATION of SERIES K JUNIOR PARTICIPATING PREFERRED STOCK of Jaguar Health, Inc. |
|
| February 27, 2025 |
Jaguar Health, Inc. and EQUINITI TRUST COMPANY, LLC, as Rights Agent RIGHTS AGREEMENT Dated as of February 26, 2025 TABLE OF CONTENTS Page Section 1. Certain Definitions 1 Section 2. Appointment of Rights Agent 8 Section 3. Issue of Right Certificates. 8 Section 4. Form of Right Certificates 10 Section 5. Countersignature and Registration. 11 Section 6. Transfer, Split Up, Combination and Exchange |
|
| February 27, 2025 |
Jaguar Health Adopts Limited Duration Stockholder Rights Plan to Ensure Stockholders Can Realize Long-Term Value Jaguar expects first results in Q2 2025 of proof-of-concept investigator-initiated trials of crofelemer for the rare diseases short bowel syndrome with intestinal failure and microvillus inclusion disease FDA meeting expected in Q2 2025 on the statistically significant results of the Phase 3 OnTarget trial of crofelemer in the prespecified subgroup of patients with breast cancer Jaguar has received an indication of interest to acquire the Company SAN FRANCISCO, CA / February 27, 2025 / Jaguar Health, Inc. |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2025 Jaguar Health, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36714 46-2956775 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 jaguar health, Inc. (Exact name of registrant as specified in its charter) Delaware 46-2956775 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 20 |
|
| February 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material under §240. |
|
| February 20, 2025 |
AMENDMENT TO SECURED PROMISSORY NOTE This Amendment to Secured Promissory Note (this “Amendment”) is entered into as of February 13, 2025, by and among Streeterville Capital, LLC, a Utah limited liability company (“Lender”), Jaguar Health, Inc. |
|
| February 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): Jaguar Health, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36714 46-2956775 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS E |
|
| February 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material under §240. |
|
| February 4, 2025 |
EX-4.1 Exhibit 4.1 AMENDMENT TO SECURED PROMISSORY NOTE This Amendment to Secured Promissory Note (this “Amendment”) is entered into as of January 29, 2025, by and among Streeterville Capital, LLC, a Utah limited liability company (“Lender”), Jaguar Health, Inc., a Delaware corporation (“Company”), and Napo Pharmaceuticals, Inc., a Delaware corporation (“Napo”, and together with Company, “Borrower |
|
| February 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 28, 2025 JAGUAR HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36714 46-2956775 (State or other jurisdiction of incorporation) (Commission Fi |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2024 Jaguar Health, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36714 46-2956775 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| November 13, 2024 |
Exhibit 10.1 November 13, 2024 Jaguar Health, Inc. 200 Pine Street, Suite 400 San Francisco, CA 94104 Attn: Lisa A. Conte, President & CEO Dear Ms. Conte: Reference is made to the At The Market Offering Agreement, dated as of December 10, 2021 (the “ATM Agreement”), between Jaguar Health, Inc. (the “Company”) and Ladenburg Thalmann & Co., Inc. (the “Ladenburg”), as amended by way of letter agreeme |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2024 Jaguar Health, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36714 46-2956775 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| November 13, 2024 |
JAGUAR HEALTH, INC. Up to $75,000,000 Shares of Common Stock Filed pursuant to Rule 424(b)(5) File No. 333-278861 Supplement No. 2 dated November 13, 2024 To Prospectus Supplement dated May 23, 2024 (To Prospectus Dated May 1, 2024) JAGUAR HEALTH, INC. Up to $75,000,000 Shares of Common Stock This supplement No. 2 amends, supplements or modifies certain information contained in the prospectus supplement, dated May 23, 2024 and as amended by the supplement N |
|
| November 13, 2024 |
Exhibit 99.1 Jaguar Health Reports Third Quarter 2024 Financial Results The combined net Q3 2024 revenue of approximately $3.1 million for prescription and non-prescription products, including license revenue, increased approximately 14% versus net Q2 2024 revenue of $2.7 million and 11% versus net Q3 2023 revenue of $2.8 million Jaguar reported significant results in breast cancer patients in its |
|
| August 13, 2024 |
Third Amendment to the Jaguar Health, Inc. New Employee Inducement Award Plan.* Exhibit 99.4 Jaguar Health, INC. THIRD AMENDMENT TO 2020 New Employee Inducement Award PLAN (Effective August 13, 2024) Jaguar Health, Inc., a Delaware corporation (the “Company”), hereby adopts this Third Amendment (this “Amendment”) to the 2020 New Employee Inducement Award Plan (as amended, the “Plan”). WITNESSETH WHEREAS, the Company’s Board of Directors (the “Board”) has adopted the Plan; WHE |
|
| August 13, 2024 |
As filed with the Securities and Exchange Commission on August 13, 2024 As filed with the Securities and Exchange Commission on August 13, 2024 Registration Statement No. |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001 |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2024 JAGUAR HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36714 46-2956775 (State or other jurisdiction of incorporation) (Commission Fil |
|
| August 13, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Jaguar Health, Inc. |
|
| August 13, 2024 |
Exhibit 99.1 Jaguar Health Reports Second Quarter 2024 Financial Results The combined net Q2 2024 revenue of approximately $2.72 million for prescription and non-prescription products increased approximately 16% versus net Q1 2024 revenue of $2.35 million and 2.0% versus net Q2 2023 revenue of $2.67 million Company to complete analysis of full data for first and second 12-week periods of pivotal p |
|
| July 23, 2024 |
Exhibit 99.1 Jaguar Health Reports Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug Crofelemer Initial results of unprecedented trial including 10 different tumor types indicate that OnTarget did not meet its primary endpoint across all tumor types. Trial did reveal clinically relevant signals for crofelemer in prespecified subgroups of patients with breast and respiratory cancer |
|
| July 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23, 2024 JAGUAR HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36714 46-2956775 (State or other jurisdiction of incorporation) (Commission File |
|
| July 18, 2024 |
Exhibit 10.1 July 17, 2024 Jaguar Health, Inc. 200 Pine Street, Suite 400 San Francisco, CA 94104 Attn: Lisa A. Conte, President & CEO Dear Ms. Conte: Reference is made to the At The Market Offering Agreement, dated as of December 10, 2021 (the “ATM Agreement”), between Jaguar Health, Inc. (the “Company”) and Ladenburg Thalmann & Co., Inc. (the “Ladenburg”), as amended by way of letter agreements |
|
| July 18, 2024 |
JAGUAR HEALTH, INC. Up to $75,000,000 Shares of Common Stock Filed pursuant to Rule 424(b)(5) File No. 333-278861 Supplement No. 1 dated July 17, 2024 To Prospectus Supplement dated May 23, 2024 (To Prospectus Dated May 1, 2024) JAGUAR HEALTH, INC. Up to $75,000,000 Shares of Common Stock This supplement amends, supplements or modifies certain information contained in the prospectus supplement, dated May 23, 2024 (the “ATM Prospectus Supplement”), and the a |
|
| July 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 17, 2024 JAGUAR HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36714 46-2956775 (State or other jurisdiction of incorporation) (Commission File |
|
| July 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 15, 2024 JAGUAR HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36714 46-2956775 (State or other jurisdiction of incorporation) (Commission File |
|
| June 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2024 JAGUAR HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36714 46-2956775 (State or other jurisdiction of incorporation) (Commission File |
|
| June 26, 2024 |
Exhibit 99.1 Jaguar Health Regains Compliance with Nasdaq’s Bid Price Requirement JAGX’s securities continue to be listed and traded on Nasdaq Jaguar to report pivotal phase 3 OnTarget trial results for its cancer supportive care drug crofelemer on or before July 23, 2024 San Francisco, CA (June 26, 2024): Jaguar Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”) today announced that on June |
|
| June 21, 2024 |
Exhibit 99.1 Jaguar Health Reports Approval of All Proposals at June 2024 Annual Meeting of Stockholders Jaguar to report pivotal phase 3 OnTarget trial results for its cancer supportive care drug crofelemer on or before July 23, 2024 Investor webcast on or before July 23 will include updates on Jaguar’s cancer supportive care portfolio, including participation from Jaguar scientific team, patient |
|
| June 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2024 JAGUAR HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36714 46-2956775 (State or other jurisdiction of incorporation) (Commission File |
|
| June 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2024 JAGUAR HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36714 46-2956775 (State or other jurisdiction of incorporation) (Commission File N |
|
| June 10, 2024 |
US47010C6075 / Jaguar Health Inc / Iliad Research & Trading, L.P. - NONE Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Jaguar Health, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 47010C805 (CUSIP Number) June 10, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designa |
|
| May 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| May 23, 2024 |
JAGUAR HEALTH, INC. Up to $75,000,000 Shares of Common Stock TABLE OF CONTENTS Filed pursuant to Rule 424(b)(5) Registration No. 333-278861 PROSPECTUS SUPPLEMENT (TO PROSPECTUS DATED MAY 1, 2024) JAGUAR HEALTH, INC. Up to $75,000,000 Shares of Common Stock We have entered into a sales agreement, dated December 10, 2021, as amended on February 2, 2022 and May 23, 2024 (the “ATM Agreement”), with Ladenburg Thalmann & Co. Inc. (“Ladenburg”) relating to share |
|
| May 23, 2024 |
Exhibit 99.1 Jaguar Health, Inc. Announces Reverse Stock Split Reverse split approved at April 2024 Special Meeting of Stockholders Shares of Jaguar Health common stock to begin trading on split-adjusted basis on May 23, 2024 San Francisco, CA (May 17, 2024): Jaguar Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”) today announced that the Company will effect a reverse stock split of its iss |
|
| May 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2024 JAGUAR HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36714 46-2956775 (State or other jurisdiction of incorporation) (Commission File N |
|
| May 23, 2024 |
Exhibit 10.1 May 23, 2024 Jaguar Health, Inc. 200 Pine Street, Suite 400 San Francisco, CA 94104 Attn: Lisa A. Conte, President & CEO Dear Ms. Conte: Reference is made to the At The Market Offering Agreement, dated as of December 10, 2021 (the “ATM Agreement”), between Jaguar Health, Inc. (the “Company”) and Ladenburg Thalmann & Co., Inc. (the “Ladenburg”), as amended by way of letter agreement da |
|
| May 23, 2024 |
Exhibit 3.1 CERTIFICATE OF EIGHTH AMENDMENT TO THE THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF JAGUAR HEALTH, INC. Jaguar Health, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies that: 1. The name of the Corporation is Jaguar Health, Inc. The date of filing of the Corporation’s original Certificate o |
|
| May 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material under §240. |
|
| May 14, 2024 |
Exhibit 10.3 FIRST AMENDMENT TO AMENDED AND RESTATED LICENSE AGREEMENT This FIRST AMENDMENT (this “Amendment”) to the Amended and Restated License Agreement (as hereinafter defined) is made effective as of March 10, 2024 (the “Amendment Effective Date”) by and between Napo Pharmaceuticals, Inc., a Delaware corporation (“Licensor”), and Napo Therapeutics S.p.A. (f/k/a Napo EU S.p.A.), an Italy law |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 00 |
|
| May 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material under §240. |
|
| May 1, 2024 |
JAGUAR HEALTH, INC. 16,666,666 Shares of Common Stock TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(3) Registration No. 333-278861 JAGUAR HEALTH, INC. 16,666,666 Shares of Common Stock Pursuant to this prospectus, the selling stockholder identified herein (the “Selling Stockholder”) is offering on a resale basis from time to time an aggregate of up to 16,666,666 shares (the “Shares”) of voting common stock, par value $0.0001 per share, of Jaguar |
|
| April 29, 2024 |
Jaguar Health, Inc. · 200 Pine Street, Suite 400 · San Francisco, CA 94104 April 29, 2024 Via EDGAR U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Jaguar Health, Inc. Registration Statement on Form S-3 File No. 333-278861 Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Jaguar Health, Inc., a Delaware corporation (the “Registrant”), hereby requests the above-referenced Registration |
|
| April 22, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Jaguar Health, Inc. |
|
| April 22, 2024 |
As filed with the Securities and Exchange Commission on April 22, 2024 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on April 22, 2024 Registration No. |
|
| April 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001- |
|
| April 9, 2024 |
Exhibit 99.1 Jaguar Health Reports Approval of All Proposals at April 2024 Special Meeting of Stockholders Company not implementing a reverse split at this time Top line results forthcoming for company’s phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy-related diarrhea San Francisco, CA (April 9, 2024): Jaguar Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”) |
|
| April 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 9, 2024 JAGUAR HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36714 46-2956775 (State or other jurisdiction of incorporation) (Commission File |
|
| April 2, 2024 |
JAGUAR HEALTH, INC. Up to $5,216,682 Shares of Common Stock Filed pursuant to Rule 424(b)(5) Registration No. 333-261283 Supplement No. 2 dated April 2, 2024 To Prospectus Supplement dated December 10, 2021 and Supplement No. 1 dated February 2, 2022 (To Prospectus Dated December 3, 2021) JAGUAR HEALTH, INC. Up to $5,216,682 Shares of Common Stock This supplement (this “Supplement”) amends and supplements the prospectus supplement, dated December 10, 2021, |
|
| April 1, 2024 |
Subsidiaries of the Registrant. Exhibit 21.1 SUBSIDIARIES OF JAGUAR HEALTH, INC. Name of Subsidiary State or Other Jurisdiction of Incorporation or Organization Napo Pharmaceuticals, Inc. Delaware Napo Therapeutics S.p.A. Italy |
|
| April 1, 2024 |
As filed with the Securities and Exchange Commission on April 1, 2024 As filed with the Securities and Exchange Commission on April 1, 2024 Registration Statement No. |
|
| April 1, 2024 |
Jaguar Health, Inc. Clawback Policy Exhibit 97 CLAWBACK POLICY Adopted: November 7, 2023 Purpose Jaguar Health, Inc. (the “Company”) is establishing this policy to align the interests of executive officers of the Company with those of shareholders, to create and maintain a culture that emphasizes integrity and accountability and to enforce the Company’s pay-for-performance compensation philosophy. This policy provides for the recoup |
|
| April 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NO. |
|
| April 1, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Jaguar Health, Inc. |
|
| March 21, 2024 |
Exhibit 99.1 GEN to Commercialize Jaguar Health’s Crofelemer in Turkey and Eight Neighboring Countries and Invest $2 Million in Jaguar Stock at 75% Premium to Market Agreement terms to include payment of double-digit royalties to Jaguar on all Crofelemer products sold in the licensed territory San Francisco, CA (March 20, 2024): Jaguar Health, Inc. (NASDAQ: JAGX) (“Jaguar”) today announced that it |
|
| March 21, 2024 |
Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2024 JAGUAR HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36714 46-2956775 (State or other jurisdiction of incorporation) (Commission File |
|
| March 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material under §240. |
|
| March 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2024 JAGUAR HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36714 46-2956775 (State or other jurisdiction of incorporation) (Commission File |
|
| March 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material under §240. |
|
| March 1, 2024 |
Exhibit 10.2 THE EXCHANGE CONTEMPLATED HEREIN IS INTENDED TO COMPORT WITH THE REQUIREMENTS OF SECTION 3(a)(9) OF THE SECURITIES ACT OF 1933, AS AMENDED. EXCHANGE AGREEMENT This Exchange Agreement (this “Agreement”) is entered into as of February 27, 2024 (the “Effective Date”) by and between [] (“Investor”), and Jaguar Health, Inc., a Delaware corporation (the “Company”). Capitalized terms used in |
|
| March 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2024 JAGUAR HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36714 46-2956775 (State or other jurisdiction of incorporation) (Commission F |
|
| March 1, 2024 |
Exhibit 10.1 THE EXCHANGE CONTEMPLATED HEREIN IS INTENDED TO COMPORT WITH THE REQUIREMENTS OF SECTION 3(a)(9) OF THE SECURITIES ACT OF 1933, AS AMENDED. EXCHANGE AGREEMENT This Exchange Agreement (this “Agreement”) is entered into as of March 1, 2024 (the “Effective Date”) by and between Streeterville Capital, LLC, a Utah limited liability company (“Investor”), and Jaguar Health, Inc., a Delaware |
|
| March 1, 2024 |
Exhibit 3.1 JAGUAR HEALTH, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES J PERPETUAL PREFERRED STOCK Pursuant to Section 151 of the General Corporation Law of the State of Delaware The undersigned, Lisa A. Conte and Carol R. Lizak, do hereby certify that: 1. They are the Chief Executive Officer/President and Chief Financial Officer, respectively, of Ja |
|
| February 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 15, 2024 JAGUAR HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36714 46-2956775 (State or other jurisdiction of incorporation) (Commission F |
|
| December 29, 2023 |
US47010C7065 / JAGUAR HEALTH INC / Iliad Research & Trading, L.P. - NONE Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a )* Jaguar Health, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 47010C706 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to |
|
| December 1, 2023 |
Exhibit 10.2 SECOND AMENDMENT TO 200 PINE STREET OFFICE LEASE This Second Amendment to 200 Pine Street Office Lease (“Second Amendment”) is made and entered into as of October 25, 2023 (“Effective Date”) by and between M & E, LLC, a California limited liability company (“Landlord”), and Jaguar Health, Inc. a Delaware corporation (“Tenant”). Landlord and Tenant are sometimes individually referred t |
|
| December 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2023 JAGUAR HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36714 46-2956775 (State or other jurisdiction of incorporation) (Commission Fi |
|
| December 1, 2023 |
Exhibit 10.1 FIRST AMENDMENT TO LEASE THIS FIRST AMENDMENT TO LEASE (this “Amendment”) is entered into as of December 24, 2021 (the “Effective Date”), by and between M & E, LLC., a California limited liability corporation (“Landlord”) and Jaguar Health, Inc., a Delaware corporation (“Tenant”), with reference to the following facts: A. Landlord and Tenant are parties to that certain Leas |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| November 8, 2023 |
Exhibit 99.1 Jaguar Health Receives Additional 180-day Grace Period to Regain Compliance with Nasdaq’s Bid Price Rule San Francisco, CA (November 8, 2023): Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that on November 8, 2023 the Company received formal notice that the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC has granted Jaguar an a |
|
| November 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2023 JAGUAR HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36714 46-2956775 (State or other jurisdiction of incorporation) (Commission Fi |
|
| October 5, 2023 |
Exhibit 4.4 GLOBAL AMENDMENT #2 This Global Amendment No. 2 (this “Amendment”) is entered into as of September 29, 2023 by and between Streeterville Capital, LLC, a Utah limited liability company (“Investor”), and Jaguar Health, Inc. a Delaware corporation (“Company”). Capitalized terms used in this Amendment without definition shall have the meanings given to them in the Royalty Interest (as defi |
|
| October 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 29, 2023 JAGUAR HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36714 46-2956775 (State or other jurisdiction of incorporation) (Commission |
|
| October 5, 2023 |
Exhibit 4.3 GLOBAL AMENDMENT #1 This Global Amendment No. 1 (this “Amendment”) is entered into as of September 29, 2023 by and between Streeterville Capital, LLC, a Utah limited liability company (“Investor”), and Jaguar Health, Inc. a Delaware corporation (“Company”). Capitalized terms used in this Amendment without definition shall have the meanings given to them in the Royalty Interest (as defi |
|
| October 5, 2023 |
Exhibit 4.2 GLOBAL AMENDMENT #2 This Global Amendment No. 2 (this “Amendment”) is entered into as of September 29, 2023 by and between Uptown Capital, LLC, a Utah limited liability company (f/k/a Irving Park Capital, LLC) (“Investor”), and Jaguar Health, Inc. a Delaware corporation (“Company”). Capitalized terms used in this Amendment without definition shall have the meanings given to them in the |
|
| October 5, 2023 |
Exhibit 4.5 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| October 5, 2023 |
Exhibit 4.1 GLOBAL AMENDMENT #2 This Global Amendment No. 2 (this “Amendment”) is entered into as of September 29, 2023 by and between Iliad Research and Trading, L.P., a Utah limited partnership (“Investor”), and Jaguar Health, Inc. a Delaware corporation (“Company”). Capitalized terms used in this Amendment without definition shall have the meanings given to them in the Royalty Interest (as defi |
|
| October 5, 2023 |
Exhibit 3.1 JAGUAR HEALTH, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES I CONVERTIBLE PREFERRED STOCK Pursuant to Section 151 of the General Corporation Law of the State of Delaware The undersigned, Lisa A. Conte and Carol R. Lizak, do hereby certify that: 1. They are the Chief Executive Officer/President and Chief Financial Officer, respectively, of |
|
| October 5, 2023 |
Exhibit 10.1 THE EXCHANGE CONTEMPLATED HEREIN IS INTENDED TO COMPORT WITH THE REQUIREMENTS OF SECTION 3(a)(9) OF THE SECURITIES ACT OF 1933, AS AMENDED. EXCHANGE AGREEMENT This Exchange Agreement (this “Agreement”) is entered into as of September 29, 2023 (the “Effective Date”) by and between Uptown Capital, LLC, a Utah limited partnership (f/k/a Irving Park Capital, LLC) (“Investor”), and Jaguar |
|
| August 14, 2023 |
Exhibit 99.1 Jaguar Health Reports Second Quarter 2023 Financial Results Net revenue increased 36% in Q2 2023 versus Q1 2023 Top line results expected late October 2023 for company’s phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy-related diarrhea Jaguar is supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of |
|
| August 14, 2023 |
Exhibit 10.7 FIRST AMENDMENT TO MANUFACTURING AND SUPPLY AGREEMENT This First Amendment (the "First Amendment") to the Manufacturing and Supply Agreement dated O1 September 2020, is made and entered into as of the date of the last signature below (the "Effective Date"), by and between Glenmark Life Sciences Limited. of 4th Floor, OJA House, 470, Cardinal Gracious Road, Andheri (E), Mumbai 400099 ( |
|
| August 14, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Jaguar Health, Inc. |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2023 JAGUAR HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36714 46-2956775 (State or other jurisdiction of incorporation) (Commission Fil |
|
| August 14, 2023 |
Exhibit 10.6 MEMORANDUM TO: INVESTOR FROM: LISA CONTE, CEO JAGUAR HEALTH, INC. SUBJECT: MODIFICATION TO THE STANDSTILL ALLOCATION DATE: FRIDAY JUNE 30TH, 2023 PURPOSE The purpose of this binding memorandum of understanding (the “MOU”) is to document an agreement by and among ILIAD RESEARCH AND TRADING, L.P., a Utah limited partnership, or its successors or assigns (“Iliad”), UPTOWN CAPITAL, LLC, a |
|
| August 14, 2023 |
As filed with the Securities and Exchange Commission on August 14, 2023 As filed with the Securities and Exchange Commission on August 14, 2023 Registration Statement No. |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001 |
|
| July 13, 2023 |
US47010C7065 / JAGUAR HEALTH INC / Fife John M. - NONE Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a )* Jaguar Health, Inc. (Name of Issuer) Common Stock, Par Value $0.0001 Per Share (Title of Class of Securities) 47010C706 (CUSIP Number) May 08, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desig |
|
| July 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2023 JAGUAR HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36714 46-2956775 (State or other jurisdiction of incorporation) (Commission File N |
|
| July 7, 2023 |
Jaguar Health Reports Approval of All Proposals at 2023 Annual Meeting of Stockholders Exhibit 99.1 Jaguar Health Reports Approval of All Proposals at 2023 Annual Meeting of Stockholders San Francisco, CA (July 7, 2023): Jaguar Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”) today announced the voting results of the Company’s 2023 Annual Meeting of Stockholders held on July 7, 2023. Five proposals were submitted to and approved by the stockholders of the Company at the Annua |
|
| July 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):June 28, 2023 JAGUAR HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36714 46-2956775 (State or other jurisdiction of incorporation) (Commission File N |
|
| July 3, 2023 |
Exhibit 3.1 JAGUAR HEALTH, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES H CONVERTIBLE PREFERRED STOCK Pursuant to Section 151 of the General Corporation Law of the State of Delaware The undersigned, Lisa A. Conte and Carol R. Lizak, do hereby certify that: 1. They are the Chief Executive Officer/President and Chief Financial Officer, respectively, of |
|
| July 3, 2023 |
Exhibit 10.2 FIRST AMENDMENT TO STANDSTILL AGREEMENT This FIRST AMENDMENT (this “Amendment”) to the Standstill Agreement (as hereinafter defined) is made effective as of June 28, 2023 (the “Amendment Effective Date”) by and among Iliad Research and Trading, L.P., a Utah limited partnership, or its successors or assigns (“Iliad”), Uptown Capital, LLC, a Utah limited liability company (f/k/a Irving |
|
| July 3, 2023 |
Exhibit 10.1 THE EXCHANGE CONTEMPLATED HEREIN IS INTENDED TO COMPORT WITH THE REQUIREMENTS OF SECTION 3(a)(9) OF THE SECURITIES ACT OF 1933, AS AMENDED. EXCHANGE AGREEMENT This Exchange Agreement (this “Agreement”) is entered into as of June 28, 2023 (the “Effective Date”) by and between [] (“Lender”), and Jaguar Health, Inc., a Delaware corporation (“Borrower”). Capitalized terms used in this Agr |
|
| May 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material under §240. |
|
| May 19, 2023 |
Second Amendment to the Jaguar Health, Inc. New Employee Inducement Award Plan. Exhibit 10.1 Jaguar Health, INC. Second AMENDMENT TO 2020 New Employee Inducement Award PLAN (Effective May 15, 2023) Jaguar Health, Inc., a Delaware corporation (the “Company”), hereby adopts this Second Amendment (this “Amendment”) to the 2020 New Employee Inducement Award Plan (as amended, the “Plan”). WITNESSETH WHEREAS, the Company’s Board of Directors (the “Board”) has adopted the Plan; WHER |
|
| May 19, 2023 |
Exhibit 99.1 Jaguar Health Announces Replenishment of New Employee Inducement Plan Under Nasdaq Listing Rule 5635(c)(4) San Francisco, CA (May 19, 2023): Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that the Company's New Employee Inducement Award Plan (the "Inducement Award Plan"), which was adopted by Jaguar's Board of Directors effective June 16, 2020, has been |
|
| May 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2023 JAGUAR HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36714 46-2956775 (State or other jurisdiction of incorporation) (Commission File N |
|
| May 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material under §240. |
|
| May 15, 2023 |
Exhibit 99.1 Jaguar Health Reports First Quarter 2023 Financial Results Net revenue decreased in Q1 2023 versus Q1 2022 Net loss improved over the same period Jaguar has agreed, as described below, not to issue additional equity securities before October 22, 2023 – by which point the Company expects to have released top line data for the Phase 3 OnTarget trial Completed and core near-term mileston |
|
| May 15, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Jaguar Health, Inc. |
|
| May 15, 2023 |
Second Amendment to the Jaguar Health, Inc. New Employee Inducement Award Plan. Exhibit 99.3 Jaguar Health, INC. Second AMENDMENT TO 2020 New Employee Inducement Award PLAN (Effective May 15, 2023) Jaguar Health, Inc., a Delaware corporation (the “Company”), hereby adopts this Second Amendment (this “Amendment”) to the 2020 New Employee Inducement Award Plan (as amended, the “Plan”). WITNESSETH WHEREAS, the Company’s Board of Directors (the “Board”) has adopted the Plan; WHER |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 00 |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2023 JAGUAR HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36714 46-2956775 (State or other jurisdiction of incorporation) (Commission File N |
|
| May 15, 2023 |
As filed with the Securities and Exchange Commission on May 15, 2023 As filed with the Securities and Exchange Commission on May 15, 2023 Registration Statement No. |
|
| May 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2023 JAGUAR HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36714 46-2956775 (State or other jurisdiction of incorporation) (Commission File N |
|
| May 9, 2023 |
Exhibit 3.1 JAGUAR HEALTH, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES G CONVERTIBLE PREFERRED STOCK Pursuant to Section 151 of the General Corporation Law of the State of Delaware The undersigned, Lisa A. Conte and Carol R. Lizak, do hereby certify that: 1. They are the Chief Executive Officer/President and Chief Financial Officer, respectively, of |
|
| May 9, 2023 |
Exhibit 10.2 STANDSTILL AGREEMENT This Standstill Agreement (this “Agreement”) is entered into as of May 8, 2023 (the “Effective Date”), by and among Iliad Research and Trading, L.P., a Utah limited partnership, or its successors or assigns (“Iliad”), Uptown Capital, LLC, a Utah limited liability company (f/k/a Irving Park Capital, LLC), or its successors or assigns (“Uptown”), Streeterville Capit |
|
| May 9, 2023 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIS |
|
| May 9, 2023 |
Exhibit 10.1 Securities PURCHASE AGREEMENT THIS Securities PURCHASE AGREEMENT (this “Agreement”), is dated as of May 8, 2023, by and among Jaguar Health, Inc., a Delaware corporation (the “Company”), and the purchasers listed on the Schedule of Purchasers attached hereto (each, a “Purchaser” and collectively, the “Purchasers”). RECITALS A. Subject to the terms and conditions set forth i |
|
| May 9, 2023 |
Exhibit 99.1 Jaguar Completes Enrollment in its Pivotal Phase 3 OnTarget Trial of Crofelemer for Prophylaxis of Cancer Therapy-Related Diarrhea Primary endpoint based on patient reported outcomes from study expected in October 2023 With the completion of the PIPE financing of unregistered shares and 6-month lock up term, Jaguar has agreed, as described below, not to issue additional equity securit |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2023 JAGUAR HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36714 46-2956775 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| April 28, 2023 |
Auditor Name RBSM, LLP Auditor Firm ID 587 Auditor Location Larkspur, California UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 6, 2023 |
As filed with the Securities and Exchange Commission on April 6, 2023 As filed with the Securities and Exchange Commission on April 6, 2023 Registration Statement No. |
|
| April 6, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Jaguar Health, Inc. |
|
| March 27, 2023 |
Exhibit 99.1 Jaguar Health Reports 2022 Financial Results – Prescription Revenues up 179% to $11.9 Million Prescription product net revenue was approximately $11.9 million for the year ended December 31, 2022 versus approximately $4.3 million for the year ended December 31, 2021, an increase of 178.7%. Prescription product net revenue of approximately $3.3 million in Q4 2022 increased 3.4% over Q3 |
|
| March 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2023 JAGUAR HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36714 46-2956775 (State or other jurisdiction of incorporation) (Commission File |
|
| March 24, 2023 |
Subsidiaries of the Registrant. Exhibit 21.1 SUBSIDIARIES OF JAGUAR HEALTH, INC. Name of Subsidiary State or Other Jurisdiction of Incorporation or Organization Napo Pharmaceuticals, Inc. Delaware Napo Therapeutics S.p.A. Italy |
|
| March 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NO. |
|
| February 23, 2023 |
US47010C7065 / JAGUAR HEALTH INC / Mailman Joshua - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Jaguar Health, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 47010C706 (CUSIP Number) February 21, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the ru |
|
| February 14, 2023 |
JAGX / Jaguar Animal Health, Inc. / Mailman Joshua - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Jaguar Health, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 47010C706 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the ru |
|
| February 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 7, 2023 JAGUAR HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36714 46-2956775 (State or other jurisdiction of incorporation) (Commission Fi |
|
| February 8, 2023 |
Exhibit 99.1 Jaguar Health Regains Compliance with Nasdaq’s Bid Price Requirement JAGX’s securities continue to be listed on Nasdaq San Francisco, CA (February 8, 2023): Jaguar Health, Inc. (Nasdaq: JAGX) ("Jaguar" or the "Company") today announced that on February 7, 2023 the Company received formal notice from The Nasdaq Stock Market LLC (“Nasdaq”) that Jaguar has regained compliance with Nasdaq |
|
| February 6, 2023 |
EX-10.1 2 tm235360d1ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 MUTUAL TERMINATION OF LICENSE AGREEMENT This Mutual Termination of License Agreement (This “Agreement”) is hereby entered into on January 31, 2023 by and among Jaguar Health, Inc., a Delaware corporation (“Licensor”), SynWorld Technologies Corporation, a corporation duly incorporated under the laws of Canada (“Licensee”), C&E Telecom, LTD, a |
|
| February 6, 2023 |
Exhibit 99.1 Jaguar Health & SynWorld Technologies Mutually Agree to Terminate License and Commercialization Agreement for Canalevia for Treatment of Diarrhea in Dogs in China Given Jaguar’s 2023 Focus on Human Drug Development February 1, 2023 Tao Wang, SynWorld's General Manager and a long-term shareholder of restricted Jaguar stock, fully aligned on termination decision SAN FRANCISCO, CA / ACCE |
|
| February 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2023 JAGUAR HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36714 46-2956775 (State or other jurisdiction of incorporation) (Commission Fi |
|
| January 23, 2023 |
Exhibit 3.1 CERTIFICATE OF SEVENTH AMENDMENT TO THE THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF JAGUAR HEALTH, INC. Jaguar Health, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies that: 1. The name of the Corporation is Jaguar Health, Inc. The date of filing of the Corporation’s original Certificate of Incorpora |
|
| January 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 20, 2023 JAGUAR HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36714 46-2956775 (State or other jurisdiction of incorporation) (Commission Fi |
|
| January 23, 2023 |
Exhibit 99.1 Jaguar Health Reports Voting Results from January 2023 Special Meeting of Stockholders All proposals approved Company announces 1-for-75 reverse stock split to support compliance with Nasdaq listing standards Shares of Jaguar Health common stock to begin trading on split-adjusted basis on January 23, 2023 Patient enrollment expected to complete in Q2 2023 for company’s pivotal Phase 3 |
|
| January 6, 2023 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2023 JAGUAR HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36714 46-2956775 (State or other jurisdiction of incorporation) (Commission Fil |
|
| December 30, 2022 |
Exhibit 10.1 FORM OF COMPANY STOCK option CANCELLATION AGREEMENT THIS COMPANY STOCK OPTION CANCELLATION AGREEMENT (this ?Agreement?) is entered into as of December [?], 2022, by and between Jaguar Health, Inc., a Delaware corporation (the ?Company?), and [?] (the ?Company Optionholder?). RECITALS WHEREAS, the Company Optionholder was granted [] compensatory stock options in the Company pursuant to |
|
| December 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 27, 2022 JAGUAR HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36714 46-2956775 (State or other jurisdiction of incorporation) (Commission F |
|
| December 16, 2022 |
? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? |
|
| November 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material under §240. |
|
| November 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material under §240. |
|
| November 16, 2022 |
Exhibit 10.1 Securities PURCHASE AGREEMENT THIS Securities PURCHASE AGREEMENT (this “Agreement”), is dated as of November 11, 2022, by and between Jaguar Health, Inc., a Delaware corporation (the “Company”), and the purchaser listed on the Schedule of Purchasers attached hereto (the “Purchaser”). RECITALS A. Subject to the terms and conditions set forth in this Agreement and pursuant to Section 4( |
|
| November 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 11, 2022 JAGUAR HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36714 46-2956775 (State or other jurisdiction of incorporation) (Commission F |
|
| November 16, 2022 |
Exhibit 3.1 JAGUAR HEALTH, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES F PREFERRED STOCK Pursuant to Section 151 of the General Corporation Law of the State of Delaware The undersigned, Lisa A. Conte and Carol R. Lizak, do hereby certify that: 1. They are the Chief Executive Officer/President and Chief Financial Officer, respectively, of Jaguar Health, Inc., a |
|
| November 14, 2022 |
Exhibit 99.1 Jaguar Health Provides Company Updates and Reports 2022 Third Quarter Financials Prescription product net revenue of approximately $3.1 million in Q3 2022 increased 8.2% over Q2 2022 and increased approximately 412% over prescription product net revenue in Q3 2021 Core initiatives: · OnTarget Phase 3 clinical trial of crofelemer for prophylaxis of cancer therapy-related diarrhea (CTD) |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2022 JAGUAR HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36714 46-2956775 (State or other jurisdiction of incorporation) (Commission F |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| October 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 17, 2022 JAGUAR HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36714 46-2956775 (State or other jurisdiction of incorporation) (Commission Fi |
|
| October 21, 2022 |
Exhibit 10.1 GLOBAL AMENDMENT This Global Amendment (this ?Amendment?) is entered into as of October 17, 2022, by and among Streeterville Capital, LLC, a Utah limited liability company (?Lender?), Jaguar Health, Inc., a Delaware corporation (?Company?), and Napo Pharmaceuticals, Inc., a Delaware corporation (?Napo?, and together with Company, ?Borrower?). Capitalized terms used but not otherwise d |
|
| October 14, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 11, 2022 JAGUAR HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36714 46-2956775 (State or other jurisdiction of incorporation) (Commission Fi |
|
| October 14, 2022 |
Exhibit 10.1 AMENDED AND RESTATED license AND SERVICES AGREEMENT This AMENDED AND RESTATED LICENSE AND Services AGREEMENT (this ?Agreement?) is entered into as of October 11, 2022 (the ?Restatement Date?) by and among Jaguar Health, Inc., a Delaware corporation (?Licensor?), SynWorld Technologies Corporation, a corporation duly incorporated under the laws of Canada (?Licensee?), solely for purpose |
|
| September 30, 2022 |
Exhibit 3.1 CERTIFICATE OF SIXTH AMENDMENT TO THE THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF JAGUAR HEALTH, INC. Jaguar Health, Inc., a corporation organized and existing under the laws of the State of Delaware (the ?Corporation?), hereby certifies that: 1.?????The name of the Corporation is Jaguar Health, Inc. The date of filing of the Corporation?s original Certificate of Incorpo |
|
| September 30, 2022 |
Exhibit 99.1 Jaguar Health Reports Voting Results from 2022 Special Meeting of Stockholders All Proposals Approved San Francisco, CA (September 30, 2022): Jaguar Health, Inc. (NASDAQ: JAGX) (?Jaguar? or the ?Company?) today announced the voting results of the Company?s 2022 Special Meeting of Stockholders held on September 30, 2022. Four proposals were submitted to and approved by the stockholders |
|
| September 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2022 JAGUAR HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36714 46-2956775 (State or other jurisdiction of incorporation) (Commission |
|
| August 30, 2022 |
Exhibit 10.1 Royalty Interest Purchase Agreement This Royalty Interest Purchase Agreement (this ?Agreement?), dated as of August 24, 2022, is entered into by and between Jaguar Health, Inc., a Delaware corporation (?Company?), and Streeterville Capital, LLC, a Utah limited liability company, its successors and/or assigns (?Investor?). A. Company and Investor are executing and delivering this Agree |
|
| August 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 24, 2022 JAGUAR HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36714 46-2956775 (State or other jurisdiction of incorporation) (Commission Fil |
|
| August 30, 2022 |
Exhibit 4.1 THIS INTEREST HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?ACT?), OR UNDER THE SECURITIES LAWS OF ANY STATES IN THE UNITED STATES. THIS INTEREST IS SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE ACT AND THE APPLICABLE STATE SECURITIES LAWS, PURSUANT TO REGISTRATION OR EXEMPTION THERE |
|
| August 30, 2022 |
Exhibit 99.1 Jaguar Health Secures Additional Capital Through Sale of Royalty Rights Related to Future Crofelemer and Lechlemer Revenue Stream Transaction proceeds will be allocated to support the company's ongoing OnTarget pivotal Phase 3 clinical trial of crofelemer for prophylaxis of diarrhea in adults receiving targeted cancer therapy SAN FRANCISCO, CA / ACCESSWIRE / August 25, 2022 / Jaguar H |
|
| August 29, 2022 |
DEF 14A 1 tm2222968-2def14a.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Prox |
|
| August 26, 2022 |
US47010C6075 / Jaguar Health Inc / Streeterville Capital LLC - NONE Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a )* Jaguar Health, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 47010C607 (CUSIP Number) August 26, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to de |
|
| August 24, 2022 |
? Exhibit 10.1 ? Certain information marked as [****] has been excluded from this exhibit because it is both (i)?not material and (ii)?would be competitively harmful if publicly disclosed. ? Master Manufacturing Services Agreement June?10, 2022 ? ? ? ? Table of Contents ? ARTICLE?1 ? STRUCTURE OF AGREEMENT AND INTERPRETATION 1 ? ? ? ? 1.1. ? Master Agreement 1 1.2. ? Product Agreements 1 1.3. ? De |
|
| August 24, 2022 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 20, 2022 JAGUAR HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36714 46-2956775 (State or other jurisdiction of incorporatio |
|
| August 23, 2022 |
Exhibit 10.2 FIRST AMENDMENT TO LICENSE AND SERVICES AGREEMENT This FIRST AMENDMENT (this ?Amendment?) to the License and Services Agreement (as hereinafter defined) is made effective as of August 18, 2022 (the ?Amendment Effective Date?) by and among Jaguar Health, Inc., a Delaware corporation (?Licensor?), SynWorld Technologies Corporation, a corporation duly incorporated under the laws of Canad |
|
| August 23, 2022 |
Exhibit 10.1 Securities PURCHASE AGREEMENT THIS Securities PURCHASE AGREEMENT (this ?Agreement?), is dated as of August 18, 2022, by and among Jaguar Health, Inc., a Delaware corporation (the ?Company?), and the purchaser listed on the Schedule of Purchasers attached hereto (the ?Purchaser?). RECITALS A. Subject to the terms and conditions set forth in this Agreement and pursuant to Section 4(a)(2 |
|
| August 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 18, 2022 JAGUAR HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36714 46-2956775 (State or other jurisdiction of incorporation) (Commission Fil |
|
| August 23, 2022 |
Exhibit 3.1 JAGUAR HEALTH, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES E PREFERRED STOCK Pursuant to Section 151 of the General Corporation Law of the State of Delaware The undersigned, Lisa A. Conte and Carol R. Lizak, do hereby certify that: 1. They are the Chief Executive Officer/President and Chief Financial Officer, respectively, of Jaguar Health, Inc., a |
|
| August 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| August 19, 2022 |
Exhibit 99.1 Jaguar Health Receives Additional 180-day Grace Period to Regain Compliance with Nasdaq?s Bid Price Rule San Francisco, CA (August 19, 2022): Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that on August 18, 2022 the Company received formal notice that the Listing Qualifications Staff of The Nasdaq Stock Market LLC has granted Jaguar an additional 180-da |
|
| August 19, 2022 |
? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549? SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION? Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
